Form 4: ResMed Director Sells 2,000 Shares Under 10b5-1 Plan

ResMed Inc. Director Peter C. Farrell sold 2,000 shares of common stock for $248.83 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Peter C. Farrell, a Director and Chairman emeritus of ResMed Inc. (RMD), reported a sale of company common stock.
• On January 7, 2026, Mr. Farrell disposed of 2,000 shares of ResMed Common Stock.
• The shares were sold at a price of $248.83 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 12, 2025.
• Following this transaction, Mr. Farrell beneficially owns 66,773 shares of ResMed Common Stock directly.

Sentiment

Score: 5

Explanation: A neutral score is assigned because the transaction is a pre-planned sale under a 10b5-1 plan, which typically indicates personal financial management rather than a reaction to new company-specific information. While a sale reduces insider ownership, the planned nature mitigates immediate negative sentiment.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned sale rather than an immediate reaction to new, undisclosed information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

Industry Context

This insider transaction is specific to a director's personal investment strategy and does not directly reflect broader industry trends or competitive dynamics within the medical device or sleep apnea treatment sectors. Such planned sales are common for executives managing personal portfolios.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a slight negative signal, though the 10b5-1 plan mitigates concerns about immediate insider sentiment. The reduction in direct beneficial ownership is minor relative to the company's total shares outstanding.

Key Dates

Recommendation

The reported transaction is a routine, pre-planned sale by a director under a Rule 10b5-1 plan. This type of insider activity is generally for personal financial management and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on the company's underlying business performance rather than this specific insider transaction.

Keywords

ResMed, RMD, Peter C. Farrell, Insider Trading, Form 4, Stock Sale, Director Transaction, 10b5-1 Plan, Medical Devices, Healthcare